[NBTY Inc.] adds another former Coca-Cola Co. executive to its management as Brian Wynne becomes Americas markets head, working with President and CEO Steve Cahillane, also a Coca-Cola veteran. The vitamin and nutritional supplement manufacturer, marketer and retailer said Dec. 8 Wynne will start in January as president of NBTY Americas and CEO of its U.S. subsidiary, United States Nutrition Inc., with general management responsibility and profit and loss accountability for the Ronkonkoma, N.Y.-based firm’s Wholesale Brands in North and South America. Wynne is a 25-year consumer packaged goods industry veteran who most recently served as Coca-Cola’s senior VP Strategy, Franchise Relations & Transformation for North America. Cahillane left his post as president of Coca-Cola’s Americas division in December 2013 and in September took the helm of Carlyle Group-owned NBTY Also see "Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane" - Pink Sheet, 20 August, 2014..
Executive Decisions Roundup
Another Coca-Cola exec pops up at NBTY; Hussain helms Glaxo pharma globally; China TCM office veteran returns; T-Bird tabs Huang as COO; and Lee named Calif. DTSC director.
More from China
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.
The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.
US pharma leadership is painting its mission, particularly its goal to end Medicare price controls, as patriotic and essential to America’s global dominance over China, a move that seems designed to align with President Trump’s priorities.
More from Asia
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.
The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.